A new drug application was filed by Akebia Therapeutics with the FDA for vadadustat, a drug to treat anemia in adult patients not on dialysis and those that are dialysis-dependent. The FDA's review of data from its non-dialysis and dialysis trials over the next 60 days will establish if the NDA is acceptable for review, according to Akebia CEO John Butler.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.